 |
| |||
| labeled adverse events (see Guideline for Postmarketing Reporting of Adverse Drug Experiences (1992) Min$draV); anticipated adverse events (Saffron) | |||
|
| |||
| labeled adverse events (see Guideline for Postmarketing Reporting of Adverse Drug Experiences (1992) Min$draV); anticipated adverse events (Saffron) | |||